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ARF Impedes NPM/B23 Shuttling in an Mdm2-Sensitive Tumor
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The ARF tumor suppressor is widely regarded as an upstream activator of p53-dependent growth arrest and
apoptosis. However, recent findings indicate that ARF can also regulate the cell cycle in the absence of p53. In
search of p53-independent ARF targets, we isolated nucleophosmin (NPM/B23), a protein we show is required
for proliferation, as a novel ARF binding protein. In response to hyperproliferative signals, ARF is upregu-
lated, resulting in the nucleolar retention of NPM and concomitant cell cycle arrest. The Mdm2 oncogene
outcompetes NPM/B23 for ARF binding, and introduction of Mdm2 reverses ARF’s p53-independent proper-
ties: in vitro, NPM is released from ARF-containing protein complexes, and in vivo S phase progression ensues.
ARF induction by oncogenes or replicative senescence does not alter NPM/B23 protein levels but rather
prevents its nucleocytoplasmic shuttling without inhibiting rRNA processing. By actively sequestering NPM in
the nucleolus, ARF utilizes an additional mechanism of tumor suppression, one that is readily antagonized by
Mdm2.
The murine INK4a/ARF locus, encoding both the p16INK4a
and p19ARF (p14ARF in humans) tumor suppressors, exhibits
an unparalleled efficiency of organization within a mammalian
genome. Specifically, p16INK4a and p19ARF contain distinct
promoters and first exons yet splice into a shared second exon
that is translated in alternative reading frames (ARF) (33).
While both proteins clearly contribute to tumor surveillance in
mice and humans, they appear to play coordinate, yet inde-
pendent, roles within the cell cycle. p16INK4a imposes a G1/S
phase block via direct inhibition of the cdk4 and cdk6 cyclin-
dependent kinases, maintaining the active, hypophosphory-
lated state of the retinoblastoma (Rb) tumor suppressor (36).
ARF, in response to hyperproliferative signals relayed by the
expression of oncoproteins, such as Myc, E2F, E1A, and Ras,
binds and sequesters Mdm2 in the nucleolus, thereby promot-
ing p53-dependent pathways of growth arrest or apoptosis
through stabilization of the nucleoplasmic pool of p53 (3, 9,
48). Additionally, ARF directly inhibits the ubiquitination of
p53 by Mdm2, suggesting that nucleolar sequestration might
not be a requisite step in ARF’s activation of p53 (13, 46).
Mounting evidence suggests that the ARF-p53-Mdm2 path-
way is not strictly linear. Mice engineered to overexpress a Myc
transgene under the control of the immunoglobulin heavy
chain enhancer (E) develop B-cell lymphomas that exhibit
biallelic ARF deletion, mutation of p53, or Mdm2 overexpres-
sion (11). Additional molecular analysis revealed that several
tumors which lacked functional p53 also displayed Mdm2 over-
expression, arguing against a simple epistatic relationship
among ARF, p53, and Mdm2 (11). Additionally, Carnero and
colleagues showed that diminished ARF expression resulted in
bypassing of replicative senescence, whereas induction of ARF
restored ARF’s tumor-suppressive properties, even in the pres-
ence of a dominant-negative p53 mutant (7). In support of
these initial findings, two other groups have demonstrated the
physiological significance of the p53-independent ARF path-
way through examination of relevant mouse model systems.
Mice lacking ARF primarily develop lymphomas and fibrosar-
comas (18, 19); in contrast, p53-null animals consistently dis-
play lymphomas and osteosarcomas (16). Surprisingly, ARF/
p53 double-null mice exhibit multiple tumors with distinct
origins, namely, the simultaneous presentation of carcinomas
with lymphomas (45). In a corroborative study, wild-type and
p53-null mice displayed normal development of the hyaloid
vascular system in the eye, yet ARF-null and ARF/p53 double-
null animals failed to show proper regression of this structure
(27). Collectively, these data reinforce the fact that ARF and
p53 play shared, as well as unique roles, as sensors of inappro-
priate cell growth.
Clearly, genetic studies have confirmed the existence of an
alternative, p53-independent ARF tumor surveillance path-
way. In an effort to uncover novel players in this pathway, we
isolated ARF-containing protein complexes from cells devoid
of p53 and Mdm2. Here, we report the identification of nu-
cleophosmin (NPM), a nucleolar phosphoprotein and clinical
marker of highly proliferative cells, as a bona fide ARF-inter-
acting protein. Recently, two studies have also described the
formation of ARF-NPM complexes in mouse fibroblasts but
drew two differing conclusions: ARF targets NPM/B23 for
degradation (15) and/or ARF prevents rRNA processing (4).
Our data offer a contrasting view. Specifically, ARF binds and
retains NPM in the cell nucleolus, effectively impeding the
nucleocytoplasmic shuttling of NPM, resulting in subsequent
growth arrest. Importantly, Mdm2 antagonizes these effects,
thereby preventing ARF-induced withdrawal from the cell cy-
cle. Two intriguing implications of our findings are that (i)
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ARF, through its interaction with NPM, may directly access
and inhibit additional cytoplasmic growth-promoting events
and (ii) Mdm2, a well-established mediator of oncogenesis,
dictates ARF’s tumor-suppressive capacity in the absence of
functional p53.
MATERIALS AND METHODS
Cell culture. Primary mouse embryonic fibroblasts (MEFs) (initially obtained
from Gerard Zambetti, St. Jude Children’s Research Hospital) were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum, 2 mM glutamine, 0.1 mM nonessential amino acids, and 100 U of
penicillin and streptomycin (GIBCO/BRL, Gaithersburg, Md.). Virus produc-
tion and infection of primary MEFs were carried out according to methods
described previously, using retroviral helper and vector plasmids (34) provided
by Charles Sawyers (University of California—Los Angeles).
Plasmid constructs. Vectors encoding p19ARF, p19ARF 1-14, and Mdm2
(210-304) were used as previously described (44) or were subcloned into the
EcoRI sites of pEGFP-C1 plasmids (Clontech). A retroviral plasmid encoding
full-length Mdm2 was a generous gift from Martine Roussel (St. Jude’s Chil-
dren’s Research Hospital). Full-length NPM was cloned from wild-type MEF
reverse-transcribed RNAs using the following PCR primers: 5-GCGCATATG
GAAGACTCGATGGATATGGAC-3 (sense) and 5-GCGGGATCCTTAAA
GAGATTTCCTCCACTGCCAGAG-3 (antisense). The NPM PCR product
was digested with the NdeI and BamHI restriction enzymes and subcloned into
the NdeI and BamHI sites of the pET28a vector (Novagen, Madison, Wis.). The
pET28a six-histidine-tagged NPM insert was PCR subcloned using the following
primers: 5-GCGGAATTCATGGGCAGCAGCCATCATCAT-3 (sense) and
5-GCGGAATTCTTAAAGAGATTTCCTCCACTG-3 (antisense). The result-
ant PCR product was subcloned into the EcoRI site of the pSR-MSV-tkneo
retroviral vector. A retroviral vector encoding DMP1 was a generous gift from
Charles J. Sherr (St. Jude’s Children’s Research Hospital).
Nucleolar isolation and MALDI-TOF. TKO MEFs labeled with [35S]methi-
onine and infected for 96 h with retroviruses encoding hemagglutinin-tagged
ARF (HA-ARF) were harvested in ice-cold phosphate-buffered saline (PBS) and
homogenized with a glass douncer. Nucleoli were isolated as previously de-
scribed (2). Nucleoli were verified by staining them in 0.1% azure C dye (Sigma,
St. Louis, Mo.). The purified nucleoli were lysed in 25 mM Tris-HCl, pH 7.4–150
mM NaCl–1 mM MgCl2–1 mM EDTA–1% Tween-20 and sonicated with three
10-s bursts at 20% output. HA-ARF complexes were immunoprecipitated with
antibodies against the HA epitope conjugated to protein A-Sepharose (Amer-
sham, Piscataway, N.J.). Proteins were eluted with 100 mM glycine (pH 3.0),
neutralized in 1 M Tris-HCl (pH 7.4), and separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins were
transferred to polyvinylidine difluoride (PVDF) membranes (Millipore, Bedford,
Mass.) and exposed to film. Identified bands were excised and digested with 0.1
g of trypsin per ml (Promega, Rockford, Ill.) overnight at 30°C. Tryptic peptide
fragments were extracted with 60% acetonitrile and 0.1% trifluoroacetic acid
using an automated Multiprobe II system (Packard Biosciences, Meriden,
Conn.). The extracted peptides were dried under vacuum, purified with Zip
Plates (Millipore), resuspended in matrix, and subjected to matrix-assisted laser
desorption ionization–time of flight (MALDI-TOF) analysis using a Voyager DE
Pro spectrometer (Applied Biosystems, Foster City, Calif.).
Immunoprecipitation and Western blot analysis. Wild-type, DKO (p53/Mdm2
null), and TKO (ARF/p53/Mdm2 null) MEFs were infected with retroviruses
encoding MycER (a gift from J. Bishop), DMP1, ARF, or ARF 1-14 and lysed
in binding buffer (25 mM Tris-HCl, pH 8, 150 mM NaCl, 1 mM EDTA, 0.1%
NP-40, 1 mM phenylmethylsulfonyl fluoride, and 0.4 U of aprotinin) either 48
(wild type and DKO) or 96 (TKO) h after infection. For MycER infections, cells
were lysed 48 h after the addition of 4-hydroxytamoxifen (4-HT) (1 M). Anti-
body to the ARF C terminus (a gift from Charles Sherr), antibody to NPM
(Zymed, San Francisco, Calif.), or nonimmune rabbit serum (NRS) or nonim-
mune mouse serum was added to the binding reaction mixtures for 1 h at 4°C.
Immune complexes were precipitated with protein A-Sepharose and washed with
binding buffer. The precipitated proteins, as well as direct protein lysates, were
separated by SDS-PAGE and transferred to PVDF membranes preactivated in
methanol. Mdm2, ARF, NPM, and -tubulin proteins were visualized by direct
immunoblotting with 2A10, ab80 (abcam, Cambridge, United Kingdom), NPM
(Zymed), and -tubulin (Santa Cruz, Santa Cruz, Calif.) antibodies, respectively.
Immunofluorescence and confocal microscopy. Wild-type or TKO MEFs (3 
104) were seeded onto glass coverslips and infected with retroviruses encoding
MycER, tkNeo (vector), ARF, or ARF in combination with Mdm2 or NPM. The
cells were fixed 96 h after infection (TKO MEFs) or 48 h after the addition of
4-hydroxytamoxifen (MycER-infected wild-type MEFs) with ice-cold methanol-
acetone (1:1 [vol/vol]) and stained for 1 h with either a rabbit ARF C-terminal
antibody (4 g per ml), human fibrillarin (Sigma), or mouse NPM antibody (4 g
per ml), followed by fluorescein isothiocyanate (FITC)-conjugated anti-mouse or
anti-rabbit immunoglobulin (Pierce) or tetramethyl rhodamine isothiocyanate-
conjugated anti-rabbit or anti-human immunoglobulin (Pierce). For measure-
ment of DNA replication, 5-bromodeoxyuridine (BrdU) (Sigma) was added to
the culture medium 72 h after infection at a final concentration of 10 M.
Twenty-four hours after the addition of BrdU, the cells were fixed in ice-cold
methanol-acetone as described above, treated for 10 min with 1.5 N HCl, and
stained for 1 h with a mouse monoclonal anti-BrdU antibody (Amersham),
followed by FITC-conjugated anti-mouse immunoglobulin (Pierce). Nuclei were
visualized with DAPI (4,6-diamidino-2-phenylindole) (Sigma). At least 100 cells
were counted on each of three coverslips for all experimental conditions. Fluo-
rescence signals were detected using a Nikon epifluorescent compound micro-
scope (100) fitted with a Nikon FDX-35 charge-coupled device camera.
FPLC. ARF synthetic peptides were coupled to cyanogen bromide-activated
Sepharose (Amersham) and equilibrated as previously described (44). TKO
lysates (200 g) were injected at a flow rate of 1.0 ml per min, washed with 20 ml
of 25 mM Tris-HCl (pH 7.4) at 1.0 ml per min, and eluted with a 25 ml of NaCl
gradient (0 to 1.5 M) at 1.0 ml per min, followed by 20 ml of 100 mM glycine (pH
3.0) at 1.0 ml per min, using BioLogic fluid phase liquid affinity chromatography
(FPLC) and BioLogic HR software (Bio-Rad, Hercules, Calif.). The 1.0-ml
collected fractions were precipitated with trichloroacetic acid, resuspended in 1
M Tris-HCl (pH 8.0), and electrophoretically separated on denaturing polyacryl-
amide gels containing SDS. The separated proteins were transferred to PVDF
membranes, and individual proteins were detected using antibodies to cyclin A
(Santa Cruz), fibrillarin (Sigma), NPM (Zymed), and Mdm2 (2A10).
Heterokaryon assay. HeLa cells (2  105) were seeded onto glass coverslips in
six-well plates and transfected with His-NPM alone or in combination with green
fluorescent protein (GFP)-ARF, GFP-ARF N62, or GFP-ARF 1-14. As a
positive shuttling control, Myc-tagged NPC-M9 (a gift from J. Alan Diehl, Uni-
versity of Pennsylvania) was transfected in combination with GFP-ARF N62.
NIH 3T3 cells (6  105) were seeded onto the HeLa cells 24 h posttransfection
and cocultured for an additional 16 h at 37°C. The cocultures were then incu-
bated for 30 min with DMEM containing cycloheximide (100 g per ml). For
fusion of mouse and human plasma membranes, the medium was removed and
the cells were incubated with 50% polyethylene glycol in PBS (prewarmed to
37°C) for 105 s, followed by three PBS washes (prewarmed to 37°C). The
cocultures were incubated with DMEM containing cycloheximide (100 g per
ml) for an additional 4 h to permit protein shuttling. Heterokaryons were fixed
with formalin-methanol (10% [vol/vol] in H2O) for 15 min and permeabilized
with 1% NP-40 in PBS for 5 min at room temperature, followed by three PBS
washes. The cells were then blocked for 1 h with 5% fetal bovine serum in PBS
and stained for 1 h with a rabbit anti-His antibody (1:25; Santa Cruz) or mouse
anti-myc antibody (1:10; Santa Cruz), followed by either FITC-conjugated anti-
rabbit or -mouse immunoglobulin (Pierce) or rhodamine X-conjugated anti-
rabbit or -mouse immunoglobulin (Pierce) for 30 min. Nuclei were stained with
DAPI. Fluorescent signals were detected using a Nikon epifluorescent com-
pound microscope (100) fitted with a Nikon FDX-35 charge-coupled device
camera.
rRNA processing. HeLa cells (106) were seeded onto 60-mm-diameter dishes
and transfected with plasmids encoding GFP or GFP-ARF. The cells were
pulse-labeled for 45 min with [5,6-3H]uridine (Amersham) and chased with
complete medium for 1 h as previously described (39). Total RNA was harvested
from cells using Trizol (GIBCO), and labeled rRNAs (2,000 cpm/lane) were
separated on 1% formaldehyde-agarose gels. The gels were denatured for 20 min
(0.05 N NaOH, 0.15 M NaCl) and neutralized for 30 min (0.1 M Tris, pH 7.5,
0.15 M NaCl) before being transferred to Hybond N membranes. Labeled
rRNAs were visualized on EN3HANCE (Perkin-Elmer)-sprayed membranes
using standard autoradiography.
RNA interference. The following 19-nucleotide duplex, corresponding to nu-
cleotides 133 to 151 downstream of the murine NPM transcriptional start site,
was synthesized and cloned into the pSUPER.retro plasmid vector (Oligo-
Engine, Seattle, Wash.) according to the manufacturer’s instructions: 5-AGAA
CGGTCAGTTTAGGAG-3 (sense) and 5-CTCCTAAACTGACCGTTCT-3
(antisense). Retroviruses encoding NPM-targeting small interfering RNAs
(siRNAs) were generated via cotransfection of pSUPER.retro-NPM RNA in-
terference (RNAi) and helper plasmids into packaging cells as described above.
TKO MEFs seeded onto 100-mm-diameter dishes were infected with pSUPER-
NPM RNAi retroviruses and subjected to Western blotting and indirect immu-
nofluorescent analyses 96 h after retroviral transduction, using antibodies de-
9328 BRADY ET AL. MOL. CELL. BIOL.
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scribed above. For indirect immunofluorescent analysis of NPM expression and
BrdU incorporation, cells infected on 100-mm-diameter dishes were seeded onto
glass coverslips (105 per coverslip) 24 h after infection, followed by addition of
BrdU (10 M), fixation, and staining for NPM and BrdU at 96 h posttransduc-
tion, as described above. Nuclei were demarcated with DAPI, and fluorescence
was visualized as described above. As a control, TKO MEFs were infected with
empty siRNA vector and scrambled siRNAs (gifts from Helen Piwnica-Worms)
(5-AGGGATGTGTCCCCTTGTG-3 [sense] and 5-CTCTTGGGGTCTCTT
CCC-3 [antisense]) and were assayed in parallel with those infected with pSU-
PER-NPM RNAi retroviruses.
RESULTS
MALDI-TOF analysis reveals that NPM is a component of
the ARF complex in vivo. ARF antagonizes the numerous
functions of Mdm2, including the ubiquitination (13, 28, 46)
and nuclear export of p53 (41), via direct binding of two con-
served domains within ARF to two central regions within
Mdm2 (6, 10, 26, 44). Through this interaction, ARF mobilizes
Mdm2 into the cell nucleolus, permitting nucleoplasmic accu-
mulation of active p53 molecules (25, 26, 41, 43). However, in
limited settings, nucleolar sequestration of Mdm2 appears not
to be required for ARF’s activation of p53 (21, 24).
To establish the biochemical composition of an Mdm2-free
ARF complex, we infected MEFs derived from mice lacking
ARF, p53, and Mdm2 (TKO) with retroviruses encoding HA-
ARF and labeled cellular proteins with [35S]methionine. To
reduce nonspecific binding of abundant cytoplasmic and nu-
clear proteins during cell lysis, HA-ARF complexes were iso-
lated from purified nucleoli. Intact nucleoli (Fig. 1A, inset)
were lysed, and ARF-containing protein complexes were pre-
cipitated using antibodies against the HA moiety (Fig. 1A).
HA-ARF is difficult to detect at 20 kDa due to its extreme
lack of methionine and cysteine residues. Proteins within ARF
complexes were separated via SDS-PAGE, digested with tryp-
sin to obtain individual peptide fragments, and combined with
matrices. Dried matrix-peptide mixtures were subjected to
MALDI-TOF analysis. Peptide masses obtained from a pro-
tein band at 38 kDa matched the peptide fingerprint for
murine NPM (Fig. 1A). An abundant nucleolar phosphopro-
tein, NPM is upregulated in response to mitogenic signals (12,
20) and is necessary for entry into S phase of the cell cycle in
established fibroblast cell lines (17). NPM’s reported role as a
marker of cell proliferation prompted us to further investigate
its association with the ARF tumor suppressor.
We next examined the ARF-NPM interaction in a physio-
FIG. 1. NPM interacts with ARF in response to hyperproliferative
signals. (A) TKO (p53/ARF/Mdm2 null) MEFs infected with retrovi-
ruses encoding HA-tagged ARF in the presence of [35S]methionine
were harvested in cold PBS. Nucleoli were isolated from TKO extracts
(inset), and purified nucleolar proteins were immunoprecipitated (IP)
with nonimmune rabbit serum or antibodies recognizing the HA
epitope. The indicated radiolabeled protein band at 38 kDa was
excised, digested with trypsin, and resuspended in matrices. The sam-
ple was subjected to MALDI-TOF analysis, and resultant tryptic pep-
tide molecular masses were entered into the Prospector Database
search engine for protein identification. (B) DKO (p53/Mdm2-null)
and wild-type (WT) MEFs infected with retroviruses encoding DMP1
or tamoxifen-inducible MycER were harvested and lysed 48 h after
infection (DMP1) or induction (MycER) with 4-HT. NPM and ARF
proteins were immunoprecipitated with NRS, normal mouse serum
(NMS), monoclonal antibody to NPM, or a rabbit polyclonal antibody
directed to the ARF C terminus (ARF). Precipitated proteins were
electrophoretically separated on denaturing gels, transferred to PVDF
membranes, and immunoblotted with the indicated antibodies. Protein
induction and loading controls are shown below each IP for each
condition. (C) Sf9 insect cells infected for 48 h with baculoviruses
encoding Mdm2 and ARF or Mdm2 and NPM were harvested and
lysed. Mdm2, ARF, and NPM proteins were immunoprecipitated with
NRS, monoclonal antibody to Mdm2 (2A10), monoclonal antibody to
NPM, or a polyclonal antibody directed to the ARF C terminus
(ARF). Precipitated proteins were electrophoretically separated on
denaturing gels, transferred to PVDF membranes, and immunoblotted
with the same antibodies.
VOL. 24, 2004 ARF PREVENTS NPM/B23 SHUTTLING 9329
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logically relevant in vivo setting, in which hyperproliferative
signals were used to induce endogenous ARF expression in
MEFs possessing an intact ARF locus. Specifically, MEFs de-
rived from p53/Mdm2-null mice (DKO) were infected with
retroviruses encoding the DMP1 transcription factor, a direct
activator of the ARF promoter in response to hyperprolifera-
tive signals such as myc (14). DMP1 transduction resulted in
the upregulation of ARF protein levels, and subsequent coim-
munoprecipitation experiments, using antibodies raised
against ARF or NPM, demonstrated the in vivo formation of
the ARF-NPM protein complex (Fig. 1B, left). Similarly, wild-
type MEFs infected with retroviruses encoding a tamoxifen-
inducible form of the myc oncoprotein (MycER) displayed
increased ARF protein levels upon treatment with 4-HT, and
coimmunoprecipitation experiments again verified the ARF-
NPM interaction (Fig. 1B, middle and right). As expected,
induction of ARF in wild-type MEFs also resulted in the co-
immunoprecipitation of Mdm2 with ARF (Fig. 1B, middle).
To ensure that Mdm2 was not mediating the ARF-NPM in-
teraction in wild-type MEFs via potential formation of ternary
complexes, we investigated whether NPM could bind directly
to Mdm2. Whereas ARF readily complexed with Mdm2, NPM
failed to bind to Mdm2 (Fig. 1C), demonstrating that the
ARF-NPM and ARF-Mdm2 interactions represent distinct
and independent protein complexes.
ARF colocalizes with NPM in the granular region of the
nucleolus. In mouse and primary diploid human cells, ARF is
expressed at low basal levels and localizes to the granular
region of the nucleolus (21, 25, 32, 43), a subnuclear organelle
that is readily detected upon immunostaining for fibrillarin.
NPM, a highly abundant nucleolar protein, localizes primarily
to fibrillarin-positive nucleoli, but additional staining through-
out the nucleus is observed (Fig. 2A and C). To corroborate
our finding that ARF and NPM interact and reside within the
same protein complex, we next wanted to verify that NPM
colocalizes with ARF in the granular region of the nucleolus
under conditions of ARF induction in vivo. As expected, myc-
mediated upregulation of endogenous ARF in wild-type MEFs
resulted in the accumulation of ARF in nucleoli, as indicated
by the colocalization of ARF with fibrillarin (Fig. 2A). Simi-
larly, retroviral transduction of exogenous ARF into TKO
MEFs produced a robust nucleolar pattern of ARF expression
(Fig. 2B). Coimmunostaining for NPM and ARF in myc-trans-
duced wild-type MEFs and ARF-transduced TKO MEFs re-
vealed that NPM and ARF colocalize to the granular region of
nucleoli, as confirmed by indirect immunofluorescent (Fig. 2B,
overlay) and confocal (Fig. 2C, overlay) microscopy.
ARF utilizes its extreme amino terminus in binding NPM.
The first 14 amino-terminal residues of murine ARF (ARF 1
to 14) represent the most highly conserved domain among all
ARF orthologs and are indispensable for ARF’s p53-depen-
dent and -independent properties (44, 45). To test our hypoth-
esis that NPM interacts with these functionally conserved res-
idues within ARF, we investigated whether an amino-terminal
deletion mutant lacking ARF’s first 14 residues (ARF 1-14)
could interact with NPM in vivo. TKO MEFs were infected
with retroviruses encoding full-length ARF or ARF 1-14,
followed by coimmunoprecipitation against ARF and NPM to
assess formation of the ARF-NPM complex. Whereas full-
length murine ARF readily bound NPM (Fig. 3A, upper left)
FIG. 2. ARF colocalizes with NPM in the granular region of the
nucleolus. (A) Wild-type (WT) MEFs were fixed and immunostained for
NPM, fibrillarin, and ARF to mark nucleolar structures. WT MEFs in-
fected with MycER were treated with 4-HT for 48 h to induce ARF
expression. (B) WT MEFS infected with MycER retroviruses and treated
with 4-HT were fixed and stained with antibodies against ARF (red) and
NPM (green) 48 h after 4-HT addition. TKO MEFs infected with retro-
viruses encoding ARF were fixed and stained using antibodies against
NPM (green) and the ARF C terminus (red) 96 h after infection. Nuclei
were demarcated with DAPI staining. All immunofluorescent microscopy
images in (A) and (B) were captured at100 magnification. (C) Confocal
microscopy was performed on the same ARF-infected TKO MEFs shown
in (B). Overlap of staining was verified using Adobe Photoshop (yellow).
The staining pattern shown was exhibited by	95% of cells viewed in four
independent experiments.
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ARF 1-14 failed to exhibit a significant in vivo interaction
with NPM (Fig. 3A, upper right), consistent with its inability to
induce complete cell cycle arrest in TKO MEFs (45). However,
we did observe some residual binding of this mutant (1-14)
with NPM, leaving open the possibility that other regions
within ARF may be important in mediating ARF-NPM inter-
actions in vivo. Contiguous deletion of ARF residues 26 to 37
(which define the low-affinity Mdm2 binding site) or 38 to 52
did not alter ARF-NPM complex formation (Fig. 3A, bottom),
and unlike ARF 1-14, these mutants are fully capable of
inducing cell cycle arrest (43).
Interestingly, ARF’s amino terminus, which contains several
conserved arginine residues, exhibits a local charge (pI 
 10.8)
comparable to that of the full-length ARF protein (pI 
 11.2),
suggesting that ARF, in the absence of its amino terminus,
could utilize its other positively charged regions to mediate
critical protein-protein interactions. However, previous studies
of the ARF-Mdm2 complex have demonstrated that ARF’s
selection of physiologically relevant targets is based on more
than simple electrostatic affinity (6, 10). To define the speci-
ficity of NPM’s interaction with the ARF amino terminus, we
injected whole-cell lysates from TKO MEFs onto affinity col-
umns comprised of similarly charged ARF peptides and eluted
bound proteins. Cyclins (A, B, D, and E) and their respective
catalytic cdk partners (2, 1, 4/6, and 2, respectively) do not
specifically bind to ARF (J. D. Weber, unpublished observa-
tion), and elution profiles from ARF peptide affinity columns
confirmed this (Fig. 3B, lanes 1 to 3). NPM bound to the first
14 residues of ARF and eluted in the salt gradient (Fig. 3B,
lanes 4 to 8), whereas other abundant and equally acidic nu-
cleolar proteins, such as fibrillarin, did not (Fig. 3B, lanes 1 to
3). Importantly, NPM did not interact with ARF residues 26 to
37, the low-affinity site for Mdm2 association, and also failed to
bind amino acids 156 to 169 of ARF, a region with a basic
charge content equal to that of residues 1 to 14 (Fig. 3B).
Mdm2 releases NPM from ARF-containing protein com-
plexes. Previous work established ARF’s reasonably strong
affinity for a central region of Mdm2 (residues 210 to 304) (6,
10), and interestingly, both Mdm2 and NPM interact with the
first 14 amino acids of ARF (Fig. 3B) (44). To compare the
relative binding strength of the ARF-NPM association with
that of ARF-Mdm2, we injected purified full-length NPM onto
a peptide column composed of ARF residues 1 to 14. NPM did
not interact with the Sepharose used to make the column (Fig.
4A, top, lanes 1 to 3) and was not nonspecifically outcompeted
once it was bound to the ARF 1 to 14 peptide column (Fig. 4A,
bottom, lanes 4 to 8). Once NPM had bound to the ARF
column (Fig. 4B, diagram), the column was washed with buffer
containing an excess molar amount of purified Mdm2 residues
210 to 304, which corresponds to the ARF binding domain (6,
44). Bound proteins were eluted with a salt gradient followed
by an acid wash, and the resultant fractions were subjected to
Western blot analysis for detection of NPM and Mdm2. Ini-
FIG. 3. NPM binds to the amino terminus of ARF. (A) TKO MEFs
infected with ARF, ARF 1-14, ARF 26-37, or ARF 38-52 were
harvested and lysed 96 h after infection. NPM and ARF proteins were
immunoprecipitated (IP) with NRS, monoclonal antibody to NPM, or
a polyclonal antibody directed to the ARF C terminus (ARF). Precip-
itated proteins were electrophoretically separated on denaturing gels,
transferred to PVDF membranes, and immunoblotted with the same
antibodies. (B) TKO lysates were injected onto the indicated ARF
peptide FPLC columns, washed (lanes 1 to 3), and eluted with an NaCl
gradient (lanes 4 to 8), followed by acid (lanes 9 and 10) as shown.
Trichloroacetic acid-precipitated proteins were separated on denatur-
ing polyacrylamide gels and immunoblotted with antibodies against
cyclin A, fibrillarin, and NPM.
VOL. 24, 2004 ARF PREVENTS NPM/B23 SHUTTLING 9331
 o
n
 January 6, 2014 by W








tially, NPM was retained on the ARF column yet was ex-
changed for Mdm2 in subsequent wash steps and eluted in the
flowthrough (Fig. 4B, lanes 1 to 3). Newly formed ARF-Mdm2
complexes were stable but eventually eluted under high-salt or
acidic conditions (Fig. 4B, lanes 6 to 9), demonstrating ARF’s
preference for Mdm2 over NPM as a binding partner. In
agreement with this finding, Mdm2 remained bound to the
ARF peptide column when the column was washed with buffer
containing an excess molar amount of purified full-length
NPM (Fig. 4C, lanes 6 to 9).
Mdm2 antagonizes ARF’s p53-dependent and -independent
functions. ARF induction evokes a G1 phase cell cycle arrest in
wild-type and TKO MEFs via p53-dependent and -indepen-
dent mechanisms, respectively (45). Importantly, both lines of
MEFs failed to arrest when Mdm2 was transduced in concert
with ARF (Fig. 5A), presumably due to Mdm2’s capacity to (i)
terminate the p53 response in wild-type cells and (ii) release
NPM from ARF complexes in TKO MEFs via preferential
binding of Mdm2 to nucleolar ARF (Fig. 4B and C). Consis-
tent with these findings, introduction of exogenous NPM into
ARF-transduced TKO MEFs significantly rescued the cells’
capacity to proceed through G1 and into S phase (Fig. 5B).
However, overexpression of NPM in ARF-transduced wild-
type MEFs was not sufficient to override ARF’s p53-dependent
cell cycle inhibition (Fig. 5B). Notably, this could be attributed
to ARF’s ability to induce the p53 effector, p21CIP1, in wild-
type MEFs but not in TKOs (45, 48). These findings suggest
that restoration of Mdm2 expression in ARF-transduced TKO
MEFs triggers a switch in ARF’s binding partners, prompting
NPM’s release from ARF-containing protein complexes.
Given that overexpression of NPM was sufficient to bypass
ARF-induced growth arrest in TKO MEFs but not wild-type
MEFs (Fig. 5B), we wanted to verify that ARF’s cell cycle
arrest was not mediated through simple downregulation of
NPM protein expression. In contrast to a recent report (15),
NPM protein levels were not reduced in response to ARF
transduction in TKO MEFs (Fig. 5C, right). A hallmark of
mouse cell culture-induced cellular senescence is the gradual
induction of ARF (48). ARF accumulation leads to cell cycle
arrest, and appropriately, mouse fibroblasts lacking ARF are
immortal and can be passaged indefinitely (18). To test
whether ARF accumulation lowered NPM protein levels in
this physiological setting, we passaged wild-type MEFs on a
3T3 protocol (18) and assayed for ARF and NPM protein
expression. As cells accumulated ARF protein, protein levels
of NPM failed to decline and remained steady throughout
fibroblast passaging, demonstrating that ARF does not reduce
NPM protein levels to arrest cell growth (Fig. 5C, left). This
finding, in combination with others’ observations that NPM
shuttles rapidly into the nucleus (5, 47), led us to hypothesize
that nucleolar ARF might inhibit NPM’s transit throughout
the cell, effectively negating NPM’s growth-promoting poten-
FIG. 4. NPM and Mdm2 compete for the conserved ARF amino
terminus. Affinity-purified (A and B) NPM (1 M) or (C) Mdm2 (1
M) containing residues 210 to 304 was initially loaded onto either an
empty or ARF 1 to 14 peptide affinity column and washed. Sub-
sequently, (A) nonspecific bacterial lysate, purified recombinant
(B) Mdm2 (1 M), or (C) NPM (1 M) was injected onto the ARF 1
to 14 column (arrows), washed (lanes 1 to 3), and eluted with an NaCl
gradient (0.5 to 1.5 M) (lanes 4 to 6), followed by acid (pH 3.0) (lanes
7 to 9). Fractions from the flowthrough and elution steps were col-
lected, separated on denaturing polyacrylamide gels, and immunoblot-
ted with antibodies against NPM and Mdm2 (H221).
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tial via topological restraint rather than protein degradation or
turnover.
ARF prevents NPM’s nucleocytoplasmic shuttling. As an
upstream activator of p53-dependent pathways of growth ar-
rest and apoptosis, ARF stabilizes p53 protein levels through
binding and sequestration of Mdm2 in the nucleolus, away
from nucleoplasmic pools of p53, suggesting that regulation of
protein topology may be an underlying feature of ARF-medi-
ated tumor suppression (25, 41, 43). The notion that subcellu-
lar compartmentalization can either enable or disable a
protein’s function is further supported by our present under-
standing of NPM dynamics within the cell. Previous studies
have established NPM’s participation in nucleocytoplasmic
shuttling (5, 47), while more recent work indicates that a rel-
atively small fraction of NPM appears to transit from the
nucleolus to the cytosol in a cell cycle-dependent manner (29,
42). Given that nucleolar ARF limits Mdm2’s oncogenic po-
tential by preventing its access to, and export from, the nucleus
(41, 43), we hypothesized that ARF may utilize a similar strat-
egy to inhibit NPM function, thereby achieving p53-indepen-
dent command of the cell cycle.
To address ARF’s potential role in regulating NPM traffick-
ing throughout the cell, we conducted in vivo heterokaryon
shuttling assays (41). An expression construct encoding six-
histidine-tagged full-length murine NPM (His-NPM) was tran-
siently transfected alone or in combination with green fluores-
cent protein-tagged constructs encoding either full-length
murine ARF (GFP-ARF) or ARF deletion mutants that either
retain (GFP-ARF N62) or lack (GFP-ARF 1-14) the con-
served amino terminus into asynchronously growing HeLa
cells. Mouse NIH 3T3 fibroblasts were seeded onto transfected
HeLa cells, yielding a heterogeneous human-mouse cell pop-
ulation, followed by fusion of plasma membranes and subse-
quent immunofluorescent detection of protein-shuttling
events. As evidenced by staining of DNA with DAPI, the
FIG. 5. Overexpression of Mdm2 or NPM antagonizes ARF-in-
duced cell cycle arrest. (A) Primary wild-type (WT) and TKO MEFs
were infected with retroviruses encoding tk Neo (vector), ARF,
or ARF in combination with Mdm2. The cells were labeled with BrdU
24 h prior to fixation (48 h for WT; 96 h for TKO [postinfection]). The
cells were stained with antibodies recognizing incorporated BrdU. The
error bars indicate standard deviations of at least 100 cells in three
independent experiments (*, P 	 0.005). TKO MEFs infected with
ARF in combination with Mdm2 were fixed 96 h postinfection and
stained with antibodies recognizing Mdm2 (red) and ARF (green);
regions of yellow indicate overlap of Mdm2 and ARF. Nuclei were
stained with DAPI (blue). (B) Primary wild-type (WT) and TKO
MEFs were infected with retroviruses encoding tkNeo (vector), ARF,
or ARF in combination with NPM. The cells were labeled with BrdU
24 h prior to fixation (48 h for WT; 96 h for TKO [postinfection]). The
cells were stained with antibodies recognizing incorporated BrdU. The
error bars indicate standard deviations of 100 cells counted in three
independent experiments (*, P 	 0.005). TKO MEFs infected with
ARF in combination with NPM were fixed 96 h postinfection and
stained with antibodies recognizing NPM (green) and ARF (red);
regions of yellow indicate overlap of NPM and ARF. Nuclei were
stained with DAPI (blue). (C) Wild-type MEFs were passaged on a
3T3 protocol and collected at passages 3 and 6. TKO MEFs infected
with retroviruses encoding tkNeo (vector), ARF 1-14, or ARF were
harvested and lysed 96 h postinfection. Whole-cell lysates were sepa-
rated on denaturing polyacrylamide gels, transferred to PVDF mem-
branes, and immunoblotted with antibodies recognizing NPM, ARF,
and -tubulin (loading control). NPM protein was normalized to -tu-
bulin using ImageJ software and graphed as arbitrary normalized units.
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FIG. 6. ARF prevents the nucleocytoplasmic shuttling of NPM. NIH 3T3 cells (ARF null) were seeded onto HeLa cells that had been
transfected with (A) His-NPM in combination with (B) GFP-ARF, (C) GFP-ARF N62, or (D) GFP ARF 1-14. (E) Myc-tagged NPC-M9 was
transfected in combination with GFP-ARF N62 as a shuttling control. NIH 3T3 and HeLa cell cocultures were incubated with cycloheximide for
30 min prior to membrane fusion with polyethylene glycol. Fused cells (heterokaryons) were incubated in medium containing cycloheximide for
an additional 4 h before fixation. Heterokaryon formation was verified under phase-contrast microscopy using a conventional differential
interference contrast (DIC) filter, while His-NPM and ARF proteins were visualized with antibodies against His (red [A to D]) or Myc (red [E])
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nuclei of NIH 3T3 and HeLa cells are easily distinguished by
the greater heterochromatin focus content of mouse cells
(speckled pattern) (Fig. 6, DAPI). In the absence of GFP-
ARF, NPM readily migrated from human nucleoli to mouse
nucleoli, as visualized in interspecies heterokaryons (Fig. 6A).
However, in the presence of nucleolar GFP-ARF or GFP-
ARF N62, NPM failed to shuttle and was restricted to human
nucleoli within heterokaryons (Fig. 6B and C). Conversely,
GFP-ARF 1-14, devoid of the NPM binding domain, was
unable to restrict NPM shuttling between human and mouse
nucleoli (Fig. 6D). As GFP-ARF did not hinder the nucleocy-
toplasmic trafficking of Myc-NPC-M9, an hnRNP protein that
readily shuttles (Fig. 6E) (31), our combined body of data
indicates that ARF specifically binds and sequesters NPM into
nucleolar ARF complexes to completely impede NPM nucle-
ocytoplasmic shuttling (Fig. 6F). Inhibition of NPM shuttling
was not due to reduction of NPM protein, as GFP-ARF had no
effect on NPM protein expression in HeLa cells (Fig. 6G).
Additionally, GFP-ARF did not inhibit rRNA processing of
28S, 18S, and 5.8S subunits in HeLa cells (Fig. 6H), indicating
that NPM’s roles in rRNA processing and nuclear export are
distinct and separate events.
NPM expression is required for cell cycle progression. Pre-
vious investigations into NPM function have correlated NPM
mRNA and protein levels with the cell’s growth state (12, 17),
and our data further indicate that NPM may be essential for S
phase entry. Based on our finding that NPM shuttling is re-
quired for cell cycle progression, we utilized RNA interference
methodologies to more directly assess the contribution of
NPM to cell proliferation. TKO MEFs transduced with retro-
viruses encoding NPM-targeting siRNA duplexes (pSUPER-
NPM RNAi) displayed a significant knockdown in NPM pro-
tein expression by 72 h postinfection (Fig. 7A) with no
observed increase in apoptosis (data not shown). In contrast,
the levels of -tubulin (Fig. 7A), as well as other nucleolar
proteins (data not shown), remained unchanged, demonstrat-
ing the specificity of our siRNA targeting sequence. Addition-
ally, a scrambled siRNA did not reduce NPM levels (Fig. 7A),
underscoring the fact that NPM protein expression is not in-
fluenced by introduction of nonspecific RNAi molecules. Im-
portantly, pSUPER-NPM RNAi-infected TKO MEFs that dis-
played reduced NPM protein expression were significantly
impaired in their ability to enter S phase compared to cells
infected with control viruses that exhibited normal levels of
NPM (Fig. 7B). Given that the reduction of NPM protein
expression and the inhibition of NPM’s nucleocytoplasmic
shuttling each trigger growth arrest in MEFs, we conclude that
NPM is an essential player in the process of cell cycle progres-
sion.
DISCUSSION
The nucleolus was originally described as the cell’s com-
mand center for ribosomal biosynthesis and assembly, with a
host of proteins being implicated in these processes. Nucleoli
are not constrained by a membrane but rather actively recruit
and retain proteins via arginine-lysine-rich nucleolar localiza-
tion signal domains, such as those encoded within ARF,
Mdm2, and NPM (22, 25, 43). In recent years, we have come to
appreciate that proteins can actively shuttle from the nucleolus
to various subcellular compartments in a regulated manner,
providing evidence that the nucleolus is not merely a static site
of ribosome biogenesis. While the nuclear and nucleolar func-
tions of ARF have been heavily debated, several groups have
shown that ARF can utilize nucleocytoplasmic transport to
negate Mdm2-mediated degradation of p53 in the cytoplasm;
specifically, ARF prevents the nuclear export of Mdm2 by
actively sequestering it in the nucleolus (6, 10, 25, 26, 41, 43).
It is reasonable to speculate that ARF, in its capacity as a
tumor suppressor, may employ a similar tactic to regulate
other growth-promoting proteins.
The key to ARF’s proficiency in arresting cell proliferation,
irrespective of p53 status, resides within its extreme amino
terminus, namely, the first 14 residues of the ARF amino acid
sequence. In search of additional interacting partners of this
domain, we have verified the formation of both endogenous
and exogenous ARF-NPM nucleolar complexes in primary
mouse fibroblasts. Notably, ARF utilizes these exact residues
to establish its high-affinity association with Mdm2, raising the
possibility that ARF may affiliate with two distinct nucleolar
complexes and/or represent a source of competition between
Mdm2 and NPM. Upon its induction by hyperproliferative
signals, ARF readily draws both Mdm2 and NPM into seem-
ingly independent, distinct nucleolar complexes, evidenced by
the absence of a ternary complex. However, overexpression of
Mdm2 results in the release of NPM from ARF-containing
protein complexes, suggesting that ARF’s ability to dictate
growth arrest in the presence or absence of p53 is largely
determined by the stoichiometry of its binding partners. In
light of this finding, it is appealing to think of Mdm2 as a target
of ARF suppression, as well as a dampener of persistent ARF
function. Specifically, Mdm2 may negatively regulate the p53
response through a dual mechanism: degradation of its direct
transcriptional activator, p53 (38, 40), and inhibition of ARF
function via preferential binding over NPM. We show here
that Mdm2 can antagonize both the p53-dependent and -inde-
pendent functions of ARF. By uncovering a pathway through
which Mdm2 can promote cell growth independently of its
classic upstream activator, p53, our study has exposed an un-
foreseen capacity of the Mdm2 oncoprotein.
and naturally emitting GFP spectra (green) using tetramethyl rhodamine isothiocyanate and FITC filters, respectively. The arrows indicate the
staining pattern of nucleoli. The data are representative of at least five independent heterokaryons formed for each transfection condition in three
independent experiments with the aggregate NPM shuttling events of all experiments plotted (F). HeLa cells transfected with GFP or GFP-ARF
were harvested and lysed 48 h after transfection. (G) Proteins were separated by SDS-PAGE and immunoblotted with antibodies recognizing
-tubulin, NPM, and GFP. (H) For analysis of rRNA processing, transfected cells were labeled with [5,6-3H]uridine for 45 min, followed by a 1-h
chase. RNA was harvested and separated on agarose-formaldehyde gels, transferred to membranes, and visualized by autoradiography. The arrows
indicate sizes of rRNA components.
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While NPM is an abundant nucleolar phosphoprotein, data
from our laboratory and others indicate that it is distributed
throughout the cell in discrete pools, and factors such as
NPM’s state of posttranslational modification, bound protein
partners, and subcellular localization may determine the com-
position and activity of any given NPM pool (5, 8, 22, 23, 30, 35,
47). As revealed by our data and the results of others, we
hypothesize that ARF sequesters a specific pool of NPM in the
nucleolus, preventing its transit and intended function(s) else-
where in the cell. The intrinsic growth-promoting potential of
the NPM pool immobilized within the ARF complex remains
unclear, but recent studies support several possibilities. ARF
transduction into MEFs lacking ARF and p53 (ARF/p53-null)
was shown to significantly impair the processing of rRNAs, and
this effect was strictly dependent upon the highly conserved
first 14 amino acids within ARF’s extreme amino terminus
(39). Importantly, transduction of p53 failed to reproduce this
result (39), indicating that ARF’s ability to down-regulate
rRNA processing is distinct from ARF’s established roles
within the classical ARF/p53/Mdm2 epistatic pathway. Addi-
tionally, two studies recently reported that NPM was a nucle-
olar ARF binding partner (4, 15). Both studies indirectly dem-
onstrate that ARF can prevent proper rRNA processing, but
how this might affect proper protein translation and how this
event signals proliferative arrest remain unanswered. Nonethe-
less, these findings, in combination with our data, suggest that
ARF’s interaction with NPM may facilitate contact between
ARF and the nucleolar ribosomal processing machinery, given
that NPM appears to function as an integral component of
ribosome maturation and export (30). We have further shown
that NPM shuttling is required for cell proliferation, suggesting
that ARF, via nucleolar sequestration of NPM, may not only
target rRNA processing but might also prevent the nucleolar
or nuclear export of processed rRNAs. This would be analo-
gous to an earlier hypothesis in which protein targets of the
ARF tumor suppressor may “ride the ribosome” out of the
nucleolus and into the cytoplasm to execute their growth-pro-
moting functions (37).
In an unrelated study, NPM was shown to be phosphorylated
by cyclin E/cdk2 at the centrosome, resulting in the initiation of
centrosome duplication (29). Hence, it is possible that nucle-
olar ARF, in response to hyperproliferative signals, binds and
immobilizes the NPM pool that is designated for transit to the
centrosome, consistent with our findings. However, a more
recent report failed to detect NPM in isolated centrosomes (1),
raising the possibility that other functional targets of NPM
reside within or are transported to the cytoplasm, one of which
might be the maturing ribosome itself. The models described
above warrant further investigation, but we cannot overlook
FIG. 7. Loss of NPM hinders cell cycle progression. (A) TKO
MEFs infected with retroviruses encoding NPM-targeting siRNA du-
plexes (NPM RNAi) were harvested and lysed at 24-, 48-, 72-, and 96-h
time points postinfection; as a control, uninfected cells were harvested
and lysed in parallel. Whole-cell lysates were separated on denaturing
polyacrylamide gels, transferred to PVDF membranes, and immuno-
blotted with antibodies recognizing NPM and -tubulin (loading con-
trol). (B) TKO MEFs transduced with either empty vector (dark bar),
scrambled (shaded bar), or NPM (open bar) RNAi-encoding retrovi-
ruses were seeded onto 100-mm-diameter dishes and glass coverslips at
24 h postinfection, followed by addition of BrdU (10 M) at 72 h
postinfection (for coverslips only). At 96 h postinfection, the cells were
either harvested for Western blot analysis (NPM and -tubulin) or
fixed, and subjected to indirect immunofluorescent detection of NPM
expression (red) and BrdU incorporation (green) using the antibodies
described above. Nuclei were demarcated with DAPI. The error bars
indicate standard deviations of 100 cells counted three times for each
slide (*, P 	 0.005).
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the possibility that NPM may, in addition to its ascribed roles
in ribosome biogenesis and centrosome duplication, transmit
additional growth-promoting commands and that Mdm2-me-
diated release of NPM from ARF complexes potentiates these
functions. Nonetheless, ARF, in its capacity as a tumor sup-
pressor, employs redundant mechanisms of protein binding
and topological sequestration to inhibit both p53-dependent
and -independent targets, thereby achieving control over cell
proliferation.
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